

## DAFTAR PUSTAKA

- Bassuni, W.Y., Blajchman, M.A, Al-Moshary, M.A., 2008. Why implement universal leukoreduction? *Hematol Oncol Stem Cel Ther* 1(2): 106-123.
- Biachi, M., Vaglio, S., Grazzini, G., 2016. Leucoreduction of blood components: an effective way to increase blood safety? <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918553/#>.
- Brand, A., 2001. Alloimmune platelet refractoriness: incidence declines, unsolved problems persist. *Transfusion* 41:724-726.
- Callum., J.L., Lin, Y., Pinkerton, P.H., Karkouti, K., Pendergrast, J.M., Robitaille, N., *et al.*, 2011. *Bloody easy 3: Blood transfusions, blood alternatives and transfusion reactions: a guide to transfusion medicine*. 3<sup>rd</sup> edition. Ontario Regional Blood Coordinating Network, Canada.
- Couban S, Carruthers J, Andreou P, Klama LN, Barr R, Kelton JG, Heddle NM., 2002. Platelet transfusions in children: results of a randomized, prospective, crossover trial of plasma removal and a prospective audit of WBC reduction. *Transfusion* Jun;42(6):753-8.
- Dzik, W,H., 2001. Leukoreduced products. In: Hillyer, C.D, Hillyer, K.L., Strobl, F., Jefferies, L. and Silberstein, L. (ed) 2001. *Handbook of transfusion medicine*. pp 125-8. Academic press. San Diego
- Dzik, W.H., Anderson, J.K., O'neill, E.M., Assmann, S.F., Kalish, L.A. and Stowell, C.P., 2002. A prospective, randomized clinical trial of universal WBC reduction. *Transfusion*, 42(9), pp.1114-1122.
- Dzik, W.H., Szczepiorkowski, Z.M., 2007. Leukocyte-reduced products. In: Hillyer, C.D., Silberstein, L.E., Ness P.M., Anderson, K.C., Roback, J.D., (Ed.) : *Blood Banking and Transfusion Medicine Basic Principles & Practice*. pp 359-82 . Churchill Livingstone Elsevier, Philadelphia.
- Enright, H., Davis, K., Gernsheimer, T., McCullough, J., Woodson, R., Slichter, S., 2003. Factors influencing moderate to severe reactions to PLT transfusions: experience of TRAP multicenter clinical trial. *Transfusion* 2003;43:1545-1552.
- Ferreira, A.A., Zulli, R., Soares, S., de Castro, V., Moraes-Souza, H., 2011. Identification of platelet refractoriness in oncohematologic patients. *Clinics* 66(1):35-40.
- Fung, M.K., Grossman, B.J., Hillyer, C.D., Westhoff, C.M., 2014. Technical manual. AABB, 18<sup>th</sup> ed.
- Guidelines for the use of platelet transfusions. 2003. *British Journal of Haematology* 122, 10-23.

- Goldfinger, D., Silvergleid, A., 2020. Refractoriness to platelet transfusion therapy. UpToDate.
- Hao, B., Wang, Y., Zhou, J., Shao, S., Dong, X., 2017. Comparison between the clinical efficacy of platelet concentrates derived from buffy coat and apheresis in tumor patients. *Oncology letters* 14:1445-1448.
- Harris, S., Hillyer, C., 2007. Chapter 12: Blood manufacturing: component preparation, storage, and transportation. *Blood Banking and Transfusion Medicine* 183-204.
- Heddle, N., Klama, L., Griffith, L., Roberts, R., Shukla, G., Kelton, J.G., 1993. A prospective study to identify risk factors associated with acute reactions to platelet and red cell transfusions. *Transfusion 1993-Vol 33*. No.10 794-797.
- Heddle, N.M., Blajchman, M.A., Meyer, R.M., Lipton, J.H., Walker, I.R., Sher, G.D., et al., 2002. A randomized controlled trial comparing the frequency of acute reactions to plasma-removed platelets and prestorage WBC-reduced platelets. *Transfusion* 42:556-566.
- Hellstern, P., 2008. Efficacy and adverse events of platelet transfusion-product specific differences. *Transfus Med Hemother* 35:102-105.
- Hervig, R., Seghatchian J., 2016. Leukocyte-reduced blood components: laboratory and clinical aspect. In: Simon, T.L., McCulough, J., Snyder E.L, Solheim, D.G., Strauss, R.G (Ed.). *Rossi's Principles of Transfusion Medicine*, pp.278-86. Willey Blackwell, Hoboken.
- Kumar, P., Thapliyal, R., Coshic, P., Chatterjee, K., 2013. Retrospective evaluation of adverse transfusion reactions following blood product transfusion from a tertiary care hospital: a preliminary step towards hemovigilance. *Journal of Transfusion Science* Vol 7, Issue 2.
- Mangano, M.M., Chambers, L., Kruskall, M. 1996. Limited efficacy of leukopoor platelets for prevention of febrile transfusion reactions. *Am J Clin Pathol* 1991;95:733-8.
- Müller-Steinhardt, M., Schlenke, P., Wagner, T., Klüter, H., 2000. Transfusion of platelet concentrates from pooled buffy-coats: comparison of bedside vs. prestorage leukofiltration. *Transfusion Medicine* 10, 59-65.
- Muyllle, L., Joos, M., Wouters, E., De Bock, R., Peetermand, M., 1993. Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. *Transfusion* 195-199.
- Napier, A., Chapman, J.F., Forman, K., Kelsey, P., Knowles, S.M., Murphy, M.F., et al., (British Committee for Standards in Haematology.), 1998. Guidelines on the clinical use of leucocyte-depleted blood components. *Transfusion Medicine* 8, 59-71.

- Ness, P.M., Campbell-Lee, S.A., 2001. Single donor versus pooled random donor platelet concentrates. *Hematol* 8:392-396.
- Novotny, V.M.J. 1999. Prevention and management of platelet transfusion refractoriness. *Vox Sanguinis*, 76, 1–13.
- Paglino, J.C., Pomper, G.J., Fisch, G.S., Champion, M.H., Snyder, E.L., 2004. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. *Transfusion* 44:16-24.
- Pavenski, K., Freedman, J., Semple, J., 2012. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention, and management. *Tissue Antigens* 4:237-245.
- Rebulla, P., 1993. Formulae for the definition of refractoriness to platelet transfusion. *Transfusion Medicine* 3, 91-93.
- Schrezenmeier, H., Seifried, E., 2010. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred. *The International Journal of Transfusion Medicine, Vox Sanguinis* 99, 1 – 15.
- Sharma, R.R., Marwaha, N., 2010. Leukoreduced blood components: advantages and strategies for its implementation in developing countries. *Asian J Transfus Sci.* Jan; 4(1): 3–8.
- Silvergleid, A.J., 2017. Leukoreduction to prevent complications of blood transfusion. UptoDate.
- Slivergleid, A.J., 2017. Immunologic transfusion reactions. UptoDate.
- Silvergleid, A.J., 2018. Approach to the patient with suspected acute transfusion reaction. UptoDate.
- Simon, T., Snyder, E., Stowell, C., Strauss, R., Bjarte, G., Solheim, G., 2011. *Rossi's Principles of Transfusion Medicine*. John Wiley & Sons.
- Slichter, S.J., 1997. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. *New England Journal of Medicine* 337:1861-9.
- Slichter, S.J., Davis, K., Enright, H., Braine, H., Gernsheimer, T., Kao, K., et al., 2005. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. *Blood* 105:4106-4114.
- Slichter, S.J., 2007. Evidence-based platelet transfusion guidelines. *Hematology* 2007.
- Smith, J.W, 2014. Blood component collection by apheresis. In: Fung, M.K., Grossman, B.J., Hillyer, C.D. and Westhoff, C.M. (Ed): Technical manual. 18<sup>th</sup> edition, pp: 167-78.: *American Association of Blood Banks (AABB), Bethesda, Maryland.*

- Stanworth, S.J., Navarrete, C., Estcourt, L., Marsh, J., 2015. Platelet refractoriness-practical approaches and ongoing dilemmas in patient management. *British Journal of Haematology* 171, 297-305.
- Taylor, C., Navarrete, C., Contreras, M., 2008. Immunological complications of blood transfusion. *Transfusion Alternatives in Transfusion Medicine* 10, 112-126.
- Vamvakas, E.C., Blajchman, M.A., 2009. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. *Blood* 113:3406-2417.
- Vilariño, D., Castrillo, A., Campos, A., Kilian, R., Villamayor, M., Cardoso, M., 2017. Assessment of the clinical performance of platelet concentrates treated by pathogen reduction technology in Santiago de Compostela. *Transfus Med Hemother* 44:5-9.
- Wang, R.R., Triulzi, D.J., Qu, L., 2018. Effects of prestorage vs poststorage leukoreduction on the rate of febrile nonhemolytic transfusion reactions to platelets. *Am J Clin Pathol* 138:255-259.
- Williamson, L., Wimperis, J., Williamson, P., Gooi, H., Copplestone, J., *et al.*, 1994. Bedside filtration of blood products in the prevention of HLA alloimmunization- a prospective randomized study. *Blood* 10:3028-3035.
- World Health Organization, 2016. Guidelines on management of blood and blood components as essential medicines. Geneva: World Health Organization; Geneva.
- Yazer, M., Podlosky, L., Clarke, G., Nahirniak, S., 2004. The effect of prestorage WBC reduction on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. *Transfusion* 2004;44:10-15.
- Zimring, J., Nester, T., 2013. Leukoreduction of blood products. *Transfusion Medicine and Hemostasis: Clinical and Laboratory Aspects: Second Edition* 275-278.